We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 1 of 94 for:    TAKE-IT
Previous Study | Return to List | Next Study

Transplant Regimen Adherence for Kidney Recipients by Engaging Information Technologies: The TAKE IT Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03104868
Recruitment Status : Not yet recruiting
First Posted : April 7, 2017
Last Update Posted : April 7, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
The investigators will evaluate a technology-enabled strategy designed to promote medication adherence, routinely monitor regimen use, and mobilize appropriate transplant center resources to respond early to kidney transplant recipients demonstrating inadequate adherence.

Condition or disease Intervention/treatment
Kidney Transplant Behavioral: TAKE IT Strategy

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 700 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants will be randomized to one of two arms: TAKE IT strategy or usual care.
Masking: Double (Participant, Investigator)
Masking Description:
We will blind: 1) research interviewers involved with outcomes assessment, 2) personnel involved in statistical analyses (Dr. Kwasny, Ms. Patel), 3) principal investigators (Wolf, Ladner). Site project managers will have access to study arm assignments to initiate TAKE IT components to those randomized to receive them.
Primary Purpose: Supportive Care
Official Title: Transplant Regimen Adherence for Kidney Recipients by Engaging Information Technologies: The TAKE IT Trial
Anticipated Study Start Date : October 2017
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : April 2022
Arms and Interventions

Arm Intervention/treatment
No Intervention: Usual Care
Patients in this group will receive the usual standard of care.
Experimental: Intervention
Patients in this group will receive the TAKE IT strategy components.
Behavioral: TAKE IT Strategy

The TAKE IT Strategy includes:

  1. Programming the electronic health record (EHR) to organize/simplify daily regimen schedules and generate electronic, tangible, print, low literacy medication education materials at every clinical encounter.
  2. SMS text-messaging to remind patients when to take all their medicine.
  3. A web-based patient portal that requests patients to periodically report upon their medication use, providing a continuous link between the transplant center and patient beyond routine in-person visits.
  4. EHR notifications directed to the transplant center nurse coordinator if an adherence-related problem is identified by the web-based portal assessment, who then can activate appropriate staff to respond.

Outcome Measures

Primary Outcome Measures :
  1. Rx regimen adherence score using the Patient Medication Adherence Questionnaire (PMAQ) [ Time Frame: 2 years ]
    A subjective measurement of missed medication doses

Secondary Outcome Measures :
  1. Correct dosing (per med) [ Time Frame: 2 years ]
    Properly demonstrating correct dose (# of pills), spacing (hours between doses), frequency (times per day), and total pills per day.

  2. Change in eGFR (estimated glomurular filtration rate), ml/mm [ Time Frame: 2 years ]
    Change in eGFR rate over 2 years

  3. Re-hospitalization [ Time Frame: 2 years ]
    Acute care hospitalizations post transplant

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1) age 18 or older
  • 2) within 3 months of KT (de novo) or 18-36 months post-KT (established)
  • 3) English speaking
  • 4) primarily responsible for administering own medication
  • 5) own a cell phone and comfortable receiving text messages
  • 6) access and proficiency using internet in home.

Exclusion Criteria:

  • any severe, uncorrectable vision, hearing or cognitive impairments
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03104868

Contact: Michael S Wolf, PhD 312-503-5592 mswolf@northwestern.edu

Sponsors and Collaborators
Northwestern University
Mayo Clinic
Northwestern Memorial Hospital
University of Illinois at Chicago
More Information

Responsible Party: Northwestern University
ClinicalTrials.gov Identifier: NCT03104868     History of Changes
Other Study ID Numbers: STU00204465
First Posted: April 7, 2017    Key Record Dates
Last Update Posted: April 7, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No